Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD). In GALAXI 2 (N=361) and GALAXI 3 (N ...

The Emirates Drug Establishment (EDE) has approved new indications for Guselkumab, making the UAE the second country globally to authorise the ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis.

This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

TREMFYA ® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study ...

The US Food and Drug Administration (FDA) approved guselkumab (Tremfya, Johnson & Johnson) for the treatment of adults with moderate to severe active Crohn’s disease (CD). The approval marks the ...

Johnson & Johnson announces positive results from phase 3b APEX study of Tremfya to treat adults living with active psoriatic arthritis: Spring House, Pennsylvania Monday, April 7 ...

Alert FDA OKs Guselkumab for Crohn’s Disease Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for moderately to severely ...